Advertisement

4′-EPI-Adriamycin in Metastatic Renal Cancer

  • S. D. Fosså
  • B. Wik
  • E. Bae
  • H. H. Lien
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 53)

Abstract

4′-epi-Adriamycin (4′-epi-ADR) is a stereoisomer of Adriamycin Preliminary observations have indicated cytostatic activity of 4′-epi-ADR in metastatic renal cancer (1). A phase II study was therefore performed in order to define the efficacy of 4′-epi-ADR in this malignancy.

Keywords

Renal Cancer Renal Cell Cancer Cytostatic Drug Systolic Time Interval Cytostatic Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    V. Bonafante, G. Bonadonna, F. Villani, G. Di Fronzo, A. Martini, and A.M. Casazza, Preliminary Phase I Study of 4′-Epi-Adriamycin, Cancer Treat. Rep. 63: 915 (1979).Google Scholar
  2. 2.
    A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler, Reporting Results of Cancer Treatment, Cancer 47: 207 (1981).PubMedCrossRefGoogle Scholar
  3. 3.
    J.L. Ritchie, J.W. Singer, D. Thorning, S.G. Sorensen, and G.W. Hamilton, Anthracycline Cardiotoxicity, Cancer 46: 1109 (1980).PubMedCrossRefGoogle Scholar
  4. 4.
    M.R. Bristow, J.W. Mason, M.E. Billingham, and J.R. Daniels, Doxorubicin cardiomyopathy, evaluation by phoncardiography, endomyocardial biopsy, and cardiac catheterization, Ann. Intern. Med. 88: 168 (1978).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • S. D. Fosså
    • 1
  • B. Wik
    • 2
  • E. Bae
    • 1
  • H. H. Lien
    • 1
  1. 1.The Norwegian Radium HospitalOsloNorway
  2. 2.Ullevål HospitalOsloNorway

Personalised recommendations